About US
Contact us
-
Top oncologist joins chorus of pricing critics in high-profile ASCO speechPharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response toFiercePharma's recent coverage is any indication. But the criticism just keeps on coming, even2015/6/2
-
Look for orphan drugs to keep fueling M&A, Moody's saysOrphan drugsare attractive to make thanks to premium pricing prospects, limited competition and regulatory perks. But those factors also make them attractive to buy, and they'll continue to spur M&2015/6/2
-
New standout Imbruvica data bode well for market expansion in CLLCHICAGO--Johnson & Johnson ($JNJ) and AbbVie's ($ABBV)Imbruvicahas already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lym2015/6/1
-
Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, tooCHICAGO--The data on Bristol-Myers Squibb's ($BMY) hot new immunotherapyOpdivokept rolling out Sunday at ASCO, showing that combining the drug with fellow Bristol cancer-fighterYervoyproved more effec2015/6/1
-
WSJ: FBI probes J&J over morcellator safety risksHow much did Johnson & Johnson ($JNJ) know about the risks of power morcellators--now suspended on safety concerns--before it pulled them from the market last year? That's the subject of a new inv2015/5/29
-
How well paid are pharma execs? Best in healthcare, survey showsWe know how executive pay in pharma tends to shake out: U.S. corporate chiefs get paid more than their European counterparts; execs at big-cap drugmakers reliably earn $15 million or more; and these d2015/5/29
-
Top Medicare prescribers get top payments from drugmakers: Modern HealthcarePharma companies that make payments to doctors--and the doctors who receive those payments--have repeatedly insisted there's no link between those payments and prescriptions. But data onMedicare's top2015/5/28
-
As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO saysAsBayermoves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's one that won't cost the drugmaker2015/5/28
-
GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze pricesWhenChinasaid it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But asBloombergreports, the optimism may have been premature. Yes, the price caps won't affect2015/5/27
-
Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadolineGet ready for a showdown in the irritable bowel syndrome market. Valeant Pharmaceuticals ($VRX) is set to hear from the FDA this week on a new, broader use in IBS-D for Xifaxan, a drug it bought along2015/5/27